Phase 2 Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis

 Biodexa Pharmaceuticals PLC

(“Biodexa” or the “Company”)

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the
2024 Digestive Disease Week Annual Meeting

Overall 83% non-progression rate at 6 Months

Statistically Significant decrease in overall mean polyp burden at 6 months (p=0.04)

https://www.globenewswire.com/news-release/2024/05/21/2885569/0/en/Positive-Statistically-Significant-Phase-2-Clinical-Trial-Results-of-Biodexa-s-Newly-licensed-eRapa-in-Familial-Adenomatous-Polyposis-FAP-Scheduled-for-Presentation-at-the-2024-Dig.html